Navigation Links
Tianyin Pharmaceutical Co., Inc. Authorizes $3.0 Million Stock Repurchase Program
Date:10/28/2008

CHENGDU, China, Oct. 28 /Xinhua-PRNewswire-FirstCall/ -- Tianyin Pharmaceutical, Co., Inc., (Amex: TPI), a manufacturer and supplier of modernized traditional Chinese medicine ("TCM") based in Chengdu, China, today announced that the Company's board of directors has approved a $3 million stock repurchase program.

On October 27, 2008, the Board of Directors authorized the Company to repurchase up to $3.0 million of its common stock through January 2009. The amount and timing of specific repurchases are subject to market conditions, applicable legal requirements and other factors deemed appropriate by the Company's CEO and President. Repurchases may be in open-market transactions or through privately negotiated transactions, and the repurchase program may be expanded by the Board of Directors in the future. The Company has approximately 15.5 million shares of common stock outstanding and approximately 2.5 million shares are in the public float as of today. Any shares repurchased by the Company in this program will be retired to the treasury while reducing the number of outstanding shares of its common stock.

"After careful consideration and evaluating a number of suitable investment opportunities, we believe an investment in our Company has the potential to yield a significant return for our shareholders," stated Dr. Jiang, Chairman and CEO of Tianyin. "We currently maintain a strong balance sheet, with approximately $12.1 million in net cash and equivalents as of June 30, 2008, and are also cash flow positive from operations. Taking this buyback into consideration, we will have maintained a sufficient cash balance to complete the new solid dosage production plant without the need for raising any additional capital," Dr. Jiang concluded.

About Tianyin Pharmaceuticals

Tianyin is a manufacturer and supplier of modernized Traditional Chinese Medicine ("TCM") in China. It was established in 1994 and acquired by the current management team in August 2003. It has a comprehensive product portfolio of 33 modernized TCMs and 4 generic western medicines in the market, 22 of which are listed in the highly selective National Medicine Catalog of the National Medical Insurance Program. Tianyin owns and operates two GMP manufacturing facilities and an R&D platform supported by leading Chinese academic institutions. The Company has a pipeline of 48 pharmaceutical products pending approval. Tianyin has an extensive nationwide distribution network throughout China with a sales force of 720 salespeople. Tianyin is headquartered in Chengdu, Sichuan Province with two manufacturing facilities and a total of 1,384 employees. Tianyin achieved revenue of approximately $33.5 million and net income of approximately $6 million in FY2008 ending June 30, 2008. For more information about Tianyin Pharmaceuticals, please visit http://www.tianyinpharma.com .

Safe Harbor Statement

This Press Release contains or may contain forward looking statements and information that are based upon beliefs of and information currently available to the Company's management as well as estimates and assumptions made by the Company's management. When used herein the words "anticipate", "believe", "estimate", "expect", "future", "intend", "plan" and similar expressions as they relate to the Company or the Company's management identify forward looking statements. These statements involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, intended or planned.

For more information, please contact:

For the Company:

Allen Tang, Ph.D., MBA, Assistant to the CEO

China

Tel: +86-158-2122-5642

Email: Allen.y.tang@gmail.com

Investors:

HC International, Inc.

Alan Sheinwald

US

Tel: +1-914-669-0222

Email: Alan.Sheinwald@hcinternational.net


'/>"/>
SOURCE Tianyin Pharmaceutical, Co., Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Viscorp, Inc. Announces Name Change to Tianyin Pharmaceutical Co Inc. and Begins Trading Under the Ticker OTC BB: TYNP
2. Tianyin Pharmaceutical to Present at Roth Third Annual China Discovery Tour in Beijing on May 20, 2008 at 12:40 p.m. Beijing Time
3. Tianyin Pharmaceutical Co., Inc. to Host Fiscal Year 2008 Third Quarter Earnings Conference Call on Thursday, May 15, 2008 at 9:00 a.m. EDT
4. Tianyin Pharmaceutical Co., Inc. Announces Third Quarter 2008 Financial Results
5. Tianyin Pharmaceutical Signs Over 60 New Distribution Agreements with 15 Regional Distributors
6. Tianyin Pharmaceutical Co., Inc. Completes Production for Earthquake
7. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Simvastatin Tablets
8. Tianyin Pharmaceutical Co., Inc. Announces Trading Symbol Error and Correction
9. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Laonian Kechuan Tablets
10. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
11. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2016)... (PRWEB) , ... April 30, 2016 , ... ... Dr. Carol Francis Talk Radio with Hypnotherapist, Mary O'Maley. What is hypnosis ... with habit control (substances, smoking, weight control), pain relief (chronic and acute), birthing ...
(Date:4/30/2016)... ... April 30, 2016 , ... ... News on April 4th, 2016 questioned the use of the HyProCure sinus ... as “a controversial procedure.” EOTTS-HyProCure is a minimally invasive procedure performed, when ...
(Date:4/29/2016)... ... 2016 , ... Mercy College is expanding its Graduate Business Programs to the ... due to high demand: Master of Business Administration (MBA), Master of Organizational Leadership (MSOL) ... , School of Business Graduate Program Chair Dr. Ray Manganelli said: “We believe that ...
(Date:4/29/2016)... ... April 29, 2016 , ... Shamangelic ... the addition Onnit brand Alpha BRAIN and New Mood Daily-Stress Formula for brain ... mood optimization products to the store is just one more way Shamangelic Healing ...
(Date:4/29/2016)... CA (PRWEB) , ... April 29, 2016 , ... ... advocating optimistic healthcare awareness and author of best seller "LOVE, MEDICINE and MIRACLES") ... Radio Monday, May 2, 2016 and podcasted thereafter . Dr. Bernie Siegel, ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... , Schweiz, April 27, 2016 ... Sachs CEO Forums in Zürich gab Strekin ... führenden Wirkstoffkandidaten STR001 zur Erhaltung des Resthörvermögens ... wurde, bekannt. Für die umfassende Phase-II-Doppelblindstudie mit ... Frankreich angeworben. STR001 wird während der Operation ...
(Date:4/27/2016)... 27, 2016   Zillion Group today ... technology platform, which specializes in live video consultation. ... digital products, Zillion enables companies to realize the ... to take control of their health. ... – including one-to-one, group and webcast scheduled or ...
(Date:4/27/2016)... NEW YORK , April 27, 2016 /PRNewswire/ ... OASM ), a developer of a new ... today announced positive overall survival results for Paclical/Apealea ... total of 789 patients with epithelial ovarian cancer. ... treatment groups: Paclical/Apealea in combination with carboplatin versus ...
Breaking Medicine Technology: